title: Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
abstract: OBJECTIVE
  To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC).
  
  
  METHODS
  Between April and November of 2000, 84 patients with stage III to IV HNC who met the eligibility criteria were enrolled; 76 of these patients were analyzable. Radiation consisted of 72 Gy in 42 fractions over 6 weeks (daily for 3.5 weeks, then twice a day for 2.5 weeks). Cisplatin dose was 100 mg/m(2) on days 1 and 22. Tumor and clinical status were assessed, and acute late toxicities were graded.
  
  
  RESULTS
  Sixty-five patients (86%) received both radiation and chemotherapy per protocol or with minor variations. The estimated 2-year locoregional relapse and distant metastasis rates were 34.7% and 16.1%, respectively. The estimated 2-year overall survival and disease-free survival rates were 71.6% and 53.5%, respectively. Three patients (4%) died of complications, 19 patients (25%) had acute grade 4 toxicity, and 49 patients (64%) had acute grade 3 toxicity. The 2-year cumulative incidence of late grade 3 to 5 toxicities was 51.3%.
  
  
  CONCLUSIONS
  These data showed that it was feasible to combine AFX-C with cisplatin. The compliance to therapy was high, and the locoregional control and survival rates achieved compared favorably with AFX-C alone or other concurrent chemoradiation regimens tested by the Radiation Therapy Oncology Group. A phase III trial comparing AFX-C plus cisplatin against standard radiation plus cisplatin is ongoing to determine whether the use of AFX-C in the concurrent chemoradiation setting further improves outcome.
authors.affiliation: The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA. kianang@mail.mdanderson.org
authors.forename: K Kian
authors.initials: KK
authors.lastname: Ang
authors.forename: Jonathan
authors.initials: J
authors.lastname: Harris
authors.forename: Adam S
authors.initials: AS
authors.lastname: Garden
authors.forename: Andy
authors.initials: A
authors.lastname: Trotti
authors.forename: Christopher U
authors.initials: CU
authors.lastname: Jones
authors.forename: Luis
authors.initials: L
authors.lastname: Carrascosa
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Cheng
authors.forename: Sharon S
authors.initials: SS
authors.lastname: Spencer
authors.forename: Arlene
authors.initials: A
authors.lastname: Forastiere
authors.forename: Randal S
authors.initials: RS
authors.lastname: Weber
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin